The U.S. Department of Health and Human Services said on Tuesday it would wind down mRNA vaccine development activities under its biomedical research unit.

In a report released today, Mani Foroohar from Leerink Partners maintained a Sell rating on Moderna, with a price target of $18.00. The company’s shares opened today at $28.20. Take advantage of ...

In addition to Oppenheimer, Moderna also received a Hold from Citi’s Geoff Meacham in a report issued today. However, on the same day, Bank of America Securities reiterated a Sell rating on Moderna ...

One particular S&P 500 biotech continues to stink out our writer's Stocks and Shares ISA. Is it time he chucked in the towel? The post This S&P 500 stock could surge 55% in just 12 months, according ...

The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...

The Mpox outbreak has renewed interest in Kenya from various foreign vaccine suppliers. One of the few WHO-approved Mpox ...

Growth in the Lipid Nanoparticles (LNPs) market is driven by increasing demand for mRNA-based therapeutics and advances in ...

The company posted strong second-quarter results and reaffirmed its guidance for 2025. Enbridge posted EBITDA of C$4.6 ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

While the number of COVID-19 patients is on the rise, the Korea Centers for Disease Control and Prevention has signed a ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

NEW YORK CITY, NY / ACCESS Newswire / July 30, 2025 / Uncorrelated Capital, a new alternative asset investment firm focused ...